Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **transforming growth factor beta-1 latent complex** is a multi-protein assembly in which the cytokine **TGF-β1** is secreted and stored in an inactive (latent) state in the extracellular matrix. TGF-β1 is synthesized as a precursor that includes a signal peptide, the mature cytokine sequence, and a latency-associated peptide (LAP). After proteolytic cleavage, the mature TGF-β1 remains non-covalently associated with LAP, forming the "small latent complex." For most TGF-β1, LAP is further covalently linked via disulfide bonds to a latent TGF-β binding protein (LTBP), resulting in the "large latent complex." LTBPs anchor the complex within the extracellular matrix. Activation of the latent complex—by proteolysis, integrin binding, or other mechanisms—releases mature TGF-β1 for receptor engagement and subsequent signal transduction. This complex is critical for regulating the spatial and temporal activity of TGF-β1 and dysregulation is implicated in diseases such as cancer, fibrosis, and chronic inflammation[1][2][3][4][5][6]. Key caveats: - The **latent complex is not a conventional drug target or receptor**; instead, it is a storage and regulatory form of TGF-β1, which itself is a validated target in several therapeutic contexts. - Searching for drugs, biomarkers, or safety specifically linked to the "latent complex" will yield little; such associations are generally described for TGF-β1 or its receptors, not the complex. - If a therapeutic agent is developed, it typically targets active TGF-β1 or its signaling pathway, not the latent complex specifically. This entry is marked **is_incorrect: true** because the "latent complex" refers to a structural storage form of TGF-β1, not a canonical individual therapeutic target (enzyme, receptor, transporter, etc.). Entries and structured data should typically refer to the mature active factor (TGF-β1) or the TGF-β receptor family.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transforming growth factor beta-1 latent complex (TGF-β1 latent complex).